Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Predictors of acute care utilization and acute pain treatment outcomes in adults with sickle cell disease: The role of non-hematologic characteristics and baseline chronic opioid dose
source: American journal of hematology
year: 2018
authors: Carroll CP, Cichowitz C, Yu T, Olagbaju YO, Nelson JA, Campbell T, Lanzkron S
summary/abstract:Despite its rarity in the United States, sickle cell disease accounts for a disproportionate amount of healthcare utilization and costs. The majority of this is due to acute care for painful crises. A small subpopulation of patients accounts for most these costs due to frequent visits to emergency departments and acute care facilities. Previous investigations have found that these high utilizing patients are distinguished by both a more severe disease course and certain non-hematologic characteristics, which may include higher socioeconomic status and some psychiatric and psychological characteristics. This prospective observational cohort study was undertaken to test the ability of these characteristics to prospectively predict acute pain care outcomes, including visit frequency, total opioid doses, and pain improvement at the Johns Hopkins Sickle Cell Infusion Center (SCIC).
Seventy-three participants were followed for 12 months and SCIC utilization and treatment outcomes were tabulated for 378 visits. Participants who visited the SCIC most frequently had markedly worse pain improvement despite higher within-visit opioid doses. Higher utilization was associated with indicators of greater illness severity, more aggressive treatment for sickle cell disease, higher baseline opioid doses, higher socioeconomic status, greater pain-related anxiety, and a history of psychiatric treatment. Overall, poor acute pain treatment response was associated with higher utilization and higher baseline opioid doses. The pattern of association between high utilization, poor acute care outcomes, and higher baseline opioid doses is discussed in terms of prior research and future directions.
organization: The Johns Hopkins School of Medicine, USA; The Johns Hopkins School of Medicine and Bloomberg School of Public Health, USA; University of Maryland School of Medicine, USA; University of Colorado School of Medicine, USA; University of Rochester School of Medicine and Dentistry, USADOI: 10.1002/ajh.25168
read more full text
Related Content
-
Sickle Cell Disease & Hospitalizationhttps://www.youtube.com/watch?v=G_P4Uc9w...
-
Targeted hydroxyurea education after an emergency department visit increases hydroxyurea use in children with sickle...Objective: To evaluate the impact of an...
-
The Bad Blood: My Life With Sickle Cell AnaemiaI wake up with an active volcano for a c...
-
Siri saves sick girl from Harvey floodwatersStranded outside in the rising waters of...
-
Men with sickle cell disease show significant concerns over safety while being treated for vaso-occlusive crises: pr...Background: We undertook a large multisi...
-
Latoyia Webb – Sickle Cell Disease Survivorhttps://www.youtube.com/watch?v=BPxbgqtV...
-
Don’t Be Shy About Asking to Remain in the HospitalOne of the best feelings in the world is...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.